O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+16.01%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$11.4B
AUM Growth
+$11.4B
(+11%)
Cap. Flow
-$84.1M
Cap. Flow
% of AUM
-0.74%
Top 10 Holdings %
Top 10 Hldgs %
35.43%
Holding
148
New
18
Increased
32
Reduced
23
Closed
13
Top Buys
| 1 |
Boston Scientific
BSX
|
$234M |
| 2 |
ACT.PRA
ACTAVIS PLC PFD CONV SER A (IRL)
ACT.PRA
|
$105M |
| 3 |
Bristol-Myers Squibb
BMY
|
$77M |
| 4 |
BLUE
bluebird bio
BLUE
|
$66.5M |
| 5 |
Cardinal Health
CAH
|
$57.3M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$188M |
| 2 |
AGN
ALLERGAN INC
AGN
|
$158M |
| 3 |
Merck
MRK
|
$144M |
| 4 |
Biogen
BIIB
|
$122M |
| 5 |
NPSP
NPS PHARMACEUTICALS INC
NPSP
|
$106M |
Sector Composition
| 1 | Healthcare | 85.68% |
| 2 | Technology | 0.16% |
| 3 | Financials | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$96B
| $573M | 4.89% | 8,882,800 +1,194,100 | +16% | +$77M |
|
|
2
Biogen
BIIB
$19.4B
| $510M | 4.35% | 1,206,800 -287,900 | -19% | -$122M |
|
3
Amgen
AMGN
$155B
| $487M | 4.16% | 3,049,000 +341,000 | +13% | +$54.5M |
|
|
AGN
4
DELISTED
Allergan plc
AGN
| $470M | 4.01% | 1,578,187 +89,987 | +6% | +$26.8M |
|
|
CELG
5
DELISTED
Celgene Corp
CELG
| $366M | 3.12% | 3,172,000 -485,600 | -13% | -$56M |
|
6
Gilead Sciences
GILD
$140B
| $335M | 2.86% | 3,411,400 -838,100 | -20% | -$82.2M |
|
7
HCA Healthcare
HCA
$94.5B
| $332M | 2.83% | 4,408,000 +100,000 | +2% | +$7.52M |
|
|
SHPG
8
DELISTED
Shire pic
SHPG
| $331M | 2.83% | 1,385,000 +215,000 | +18% | +$51.4M |
|
|
RLYP
9
DELISTED
RELYPSA INC COM
RLYP
| $319M | 2.73% | 8,857,551 | – | – |
|
|
ICPT
10
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $316M | 2.7% | 1,120,000 -365,000 | -25% | -$103M |
|
|
IPXL
11
DELISTED
Impax Laboratories, Inc.
IPXL
| $313M | 2.67% | 6,678,000 | – | – |
|
|
MDVN
12
DELISTED
MEDIVATION, INC.
MDVN
| $303M | 2.59% | 2,348,900 +80,000 | +4% | +$10.3M |
|
13
AbbVie
ABBV
$372B
| $282M | 2.41% | 4,814,900 -516,200 | -10% | -$30.2M |
|
14
Thermo Fisher Scientific
TMO
$186B
| $243M | 2.08% | 1,811,700 +216,000 | +14% | +$29M |
|
15
Cooper Companies
COO
$13.4B
| $242M | 2.06% | 1,290,500 +69,900 | +6% | +$13.1M |
|
16
Incyte
INCY
$16.5B
| $240M | 2.05% | 2,622,500 -526,800 | -17% | -$48.3M |
|
|
17
Boston Scientific
BSX
$156B
| $240M | 2.05% | 13,511,000 +13,191,000 | +4,122% | +$234M |
|
|
HNT
18
DELISTED
HEALTH NET INC
HNT
| $234M | 1.99% | 3,861,400 +150,000 | +4% | +$9.07M |
|
19
Molina Healthcare
MOH
$9.8B
| $233M | 1.99% | 3,459,100 -122,800 | -3% | -$8.26M |
|
20
Neurocrine Biosciences
NBIX
$13.8B
| $232M | 1.98% | 5,833,600 -135,000 | -2% | -$5.36M |
|
21
Illumina
ILMN
$15.8B
| $223M | 1.91% | 1,203,000 -273,600 | -19% | -$50.8M |
|
22
Intuitive Surgical
ISRG
$170B
| $207M | 1.77% | 409,700 -30,300 | -7% | -$15.3M |
|
23
Perrigo
PRGO
$3.27B
| $207M | 1.76% | 1,247,800 | – | – |
|
24
Ironwood Pharmaceuticals
IRWD
$214M
| $192M | 1.64% | 12,012,100 | – | – |
|
25
Regeneron Pharmaceuticals
REGN
$61.5B
| $190M | 1.63% | 421,800 +31,600 | +8% | +$14.3M |
|